)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Forte Biosciences
Forte Biosciences (FBRX) investor relations material
Forte Biosciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
FB102 clinical development advanced with multiple key data readouts expected in 2026, including phase 2 celiac disease and phase 1b studies in vitiligo and alopecia areata.
FB102 targets significant unmet needs in autoimmune diseases, representing multi-billion dollar market opportunities.
Financial highlights
Research and development expenses rose to $58.2 million in 2025 from $21.2 million in 2024, mainly due to increased clinical and manufacturing costs for FB102 trials.
General and administrative expenses decreased to $12.4 million in 2025 from $15.4 million in 2024, driven by lower professional and legal fees.
Net loss for 2025 was $69.4 million, with net loss per share at $(4.71), compared to a net loss of $35.5 million and $(12.17) per share in 2024.
Ended 2025 with $77.0 million in cash and cash equivalents.
Outlook and guidance
Anticipates topline results from phase 2 celiac disease study and phase 1b studies in vitiligo and alopecia areata in 2026.
Expects research and development expenses to increase as FB102 advances through additional trials and indications.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Forte Biosciences
- Registering 9.5M shares for resale post-$53M private placement; focus on autoimmune therapies.FBRX
Registration Filing16 Dec 2025 - Shelf registration enables up to $300M in offerings to fund autoimmune drug development.FBRXRegistration Filing16 Dec 2025
- Shareholders will vote on director elections, auditor ratification, an equity plan, and a reverse stock split.FBRXProxy Filing1 Dec 2025
- Shareholders will vote on director elections, auditor ratification, equity plan expansion, and a reverse stock split.FBRXProxy Filing1 Dec 2025
- 2025 proxy covers director elections, auditor ratification, and performance-linked executive pay.FBRXProxy Filing1 Dec 2025
- Shareholders will vote on expanding the equity plan by 3,000,000 shares to attract and retain talent.FBRXProxy Filing1 Dec 2025
- FB102 trials advance with major 2026 readouts ahead; R&D costs surge, cash at $93.4M.FBRXQ3 202514 Nov 2025
- FB102 clinical progress and strong cash position extend runway, but more funding is needed.FBRXQ2 202514 Nov 2025
- FB102 showed significant histological and symptom benefits in Phase 1B celiac disease study.FBRXStudy Update14 Nov 2025
Next Forte Biosciences earnings date
Q1 202614 May, 2026
Forte Biosciences
Next Forte Biosciences earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage